Go Pro
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel
NASDAQ:SABS

SAB Biotherapeutics 8/6/2026 Earnings Report

SAB Biotherapeutics logo
$3.77 -0.13 (-3.33%)
Closing price 07/8/2026 04:00 PM Eastern
Extended Trading
$3.75 -0.02 (-0.53%)
As of 07/8/2026 04:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

SAB Biotherapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.29
Beat/Miss
N/A
One Year Ago EPS
N/A

SAB Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.13 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

SAB Biotherapeutics Announcement Details

Quarter
Date
8/6/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

SAB Biotherapeutics Earnings Headlines

SAB Biotherapeutics, Inc.: Breakthrough T1D Awards Grant to Support PRISE-hATG Study of SAB-142 in Stage 3 Type 1 Diabetes
July 7 at 5:30 PM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/68962994-sab-biotherapeutics-inc-breakthrough-t1d-awards-grant-to-support-prise-hatg-study-of-sab-142-in-stage-3-type-1-diabetes-399.htm
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
July 7 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/07/3323094/0/en/breakthrough-t1d-awards-grant-to-support-prise-hatg-study-of-sab-142-in-stage-3-type-1-diabetes.html
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in 50 years - and it has nothing to do with a single stock. According to multiple Wall Street banks, a coming crisis could keep your portfolio in the red for 10 years or longer. Keith Kaplan, CEO of TradeSmith, is sharing what you can do to protect your wealth before it hits.tc pixel
 |  TradeSmith (Ad)
Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?
July 6 at 11:25 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/why-h-c-wainwright-bullish-220812002.html
SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
May 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/sab-bio-present-data-sab-120000405.html
SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
May 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/29/3303527/0/en/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-association-s-2026-scientific-sessions-and-focis-2026-annual-meeting.html
See More SAB Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SAB Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SAB Biotherapeutics and other key companies, straight to your email.

About SAB Biotherapeutics

SAB Biotherapeutics (NASDAQ:SABS) is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases. SAB-185, its anti-SARS-CoV-2 polyclonal antibody candidate, advanced through clinical trials for the treatment and prevention of COVID-19. In addition to its coronavirus program, SAB Biotherapeutics is exploring pipeline candidates against other emerging pathogens, including Zika virus, MERS, and chikungunya virus. Beyond infectious disease, the Tc Bovine® platform has potential applications in oncology and chronic inflammatory conditions, where diverse antibody repertoires may address antigenic variation and tumor heterogeneity.

Since its founding in 2008, SAB Biotherapeutics has pursued strategic collaborations with government agencies, academic institutions, and industry partners to accelerate development of its antibody therapeutics. The company operates its biomanufacturing and research facilities in Sioux Falls and maintains collaborations across the United States for preclinical and clinical studies. By leveraging its transchromosomic cattle system, SAB Biotherapeutics aims to provide a rapid response capability for emerging public-health threats, while building a diversified pipeline of immune-based therapies for multiple indications.

View SAB Biotherapeutics Profile
Earnings Tools